Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
aTyr Pharma aligned with FDA on a global Phase 3 protocol for efzofitimod in pulmonary sarcoidosis using FVC at week 48 as the primary endpoint; study activities are expected to begin in Q4 2026 and will require additional capital.Material DetailsContext by AI AnalystThis is a mid-cycle development…
aTyr Pharma aligned with the FDA on a Phase 3 efzofitimod trial in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. Study-related activities are expected to start in Q4 2026 as the company prepares U.S. and European regulatory submissions. Trial will test whether efzofitimod can improve lung fu